Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Accounts Receivables?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1999 - 2021 (23 years)

Accounts Receivables is 
$5.6B (1Y +11.1% )

ALXN Stock Price & Accounts Receivables

Accounts Receivables for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Accounts Receivables

chevron_right 2021 $1.4B +69.1x
( +20.3% / year avg)
chevron_left 1999 $20.1M
vertical_align_top Peak $5.4B +3854x
vertical_align_bottom Bottom $1.4M
arrow_drop_up # Up Years 17 17 of 23
years up.
arrow_drop_down # Down Years 6
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1999 , or +0.65x the rate relative to it's accounts receivables over the same period.
  • If ALXN grows it's stock at the same rate as it's accounts receivables (+20.3%/year) , it's stock price will grow +634% and hit $690.19 over the next 10 years.
  • ALXN's stock price has gone up 11 of the 17 years (+64%) it's accounts receivables were also up.
  • ALXN Historical Accounts Receivables Table
    in $ million
    Year Accounts Receivables YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $1,409 -73.9% $108.72 -4.8%
    4/1/2020 $5,397 29.2% $114.22 13.4%
    4/1/2019 $4,178 27.9% $100.76 -17.6%
    4/1/2018 $3,267 19.9% $122.24 -14.2%
    4/1/2017 $2,725 57.7% $142.41 -5.6%
    4/1/2016 $1,728 -11.9% $150.9 -7.9%
    4/1/2015 $1,960 13.5% $163.84 -1.5%
    4/1/2014 $1,727 25.2% $166.32 70.4%
    4/1/2013 $1,379 24.8% $97.58 7.7%
    4/1/2012 $1,105 37.6% $90.57 91.0%
    4/1/2011 $803 54.1% $47.42 89.6%
    4/1/2010 $521 45.3% $25.02 37.1%
    4/1/2009 $358 55.9% $18.25 2.3%
    4/1/2008 $230 414.9% $17.84 46.9%
    4/1/2007 $44 2730.9% $12.14 49.4%
    4/1/2006 $1 -60.7% $8.13 41.1%
    4/1/2005 $4 -50.7% $5.76 23.9%
    4/1/2004 $8 171.3% $4.65 9.4%
    4/1/2003 $3 114.8% $4.25 8.0%
    4/1/2002 $1 -85.7% $3.94 -34.4%
    4/1/2001 $9 25.3% $6.0 -66.4%
    4/1/2000 $7 -61.2% $17.88 633.3%
    4/1/1999 $20 - $2.44 -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Accounts receivables (also known as net receivables consist of the short-term obligations owed to the company by its clients. Companies often sell products or services to customers on credit; these obligations are held in the current assets account until they are paid off by the clients.

    For more detailed definitions, please see Investopedia.